Spoken Alpha
Aprea Therapeutics, Inc.
Aprea Therapeutics develops small molecule inhibitors targeting specific cancer-related genetic mutations to selectively kill cancer cells while sparing healthy tissue.
Aprea Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $9.6M market cap.
APRE beat consensus EPS by 0.7% in Q2 FY2026, reported Aug 11, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add APRE, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for APRE.
$ curl https://api.spokenalpha.com/v1/companies/APREFAQ
Spoken Alpha indexes APRE's earnings call transcripts at https://spokenalpha.com/companies/APRE. Each call links to attributed speakers and parsed analyst Q&A. Aprea Therapeutics, Inc.'s own investor relations page is at https://ir.aprea.com/.
Aprea Therapeutics, Inc. (APRE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-0.07 | $-0.22 | +68.2% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.22 | $-0.23 | +4.3% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-15 | $-0.32 | $-0.36 | +11.1% | $3.3K | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.47 | $-0.34 | -38.2% | $1.8K | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.53 | $-0.71 | +25.4% | $118.1K | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.66 | $-1.00 | +34.4% | $162.5K | — | — | EODHD |
| Q4 FY2024 | 2025-03-24 | $-0.49 | $-0.54 | +9.3% | $205.8K | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.64 | $-0.74 | +13.5% | $354.6K | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-0.58 | $-0.60 | +3.3% | $561.6K | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.67 | $-0.80 | +16.3% | $380.6K | — | — | EODHD |
| Q4 FY2023 | 2024-03-25 | $-0.92 | $-0.77 | -19.5% | $14.1K | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.86 | $-1.04 | +17.3% | $319.5K | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.87 | $-1.38 | +37.0% | $249.7K | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-1.34 | $-0.82 | -63.4% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-0.92 | $-3.08 | +70.1% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-2.40 | $-1.60 | -50.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-19.63 | $-6.20 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-7.20 | $-7.60 | +5.3% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-14 | $-7.20 | $-8.80 | +18.2% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-07 | $-9.00 | $-9.05 | +0.5% | $0 | — | — | EODHD |
Source: EODHD. APRE reported actuals as published; sparse fields render as —.